Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really? ??
I think admd has great potential
A lot is going on.
Vet market- new great and experienced people on the board to get fda approval
Admd?
Hotstocked. Com
From today
Immediately turn your attention to ADMD (Advanced Medical Isotope Corp. ADMD has one of the most bullish charts we’ve seen this year. After a brief period of consolidation and support coupled with news released on the company just last week, we think ADMD is primed and ready for another run north.
Currently, StockTA has ADMD showing “Bullish” EMA and MACD signals for all terms (short, intermediate and long)! StockTA also reports an overall “Bullish” analysis while BarChart.com shows the majority of its composite indicators giving a “Buy” signal!
One glance at ADMD’s chart and it’s apparent that something big is brewing. We've already seen ADMD breach hundreds of thousands of dollars in resistance to close at new 52 week highs multiple days earlier in April! Currently at .008, ADMD could be the best bargain of 2016, but we wouldn’t wait too long as prices could soar in coming sessions!
Now that you know how impressive ADMD is from a technical chart standpoint, just wait until you hear the fundamentals!
Advanced Medical Isotope Corp. (ADMD) a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. ADMD 's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.Since late 2013, ADMD has focused its resources on developing a proposed line of brachytherapy products and on endeavoring to secure FDA clearance with respect to the initial proposed brachytherapy product.
ADMD’s proposed brachytherapy products incorporate patented technology developed for Battelle Memorial Institute (“Battelle”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted ADMD an exclusive license to patents covering these developments for manufacturing, processing and applications for medical isotopes (the “Battelle License”).
A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead ADMD’s development efforts. ADMD has been recognized as a leader in the development of new isotope technologies by local, state and federal agencies.
ADMD’s overall objective is to empower physicians, medical researchers, and ultimately, patients, by providing them with essential radionuclides that, until now, have not been practical or economical to produce, in an effort to detect, manage, and cure human disease, and improve the lives of patients. ADMD’s shorter-term objective is to obtain regulatory approval for its brachytherapy products and to then commercialize those products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Y-90 brachytherapy product is able to target cells within a narrow range, minimizing damage to normal cells. Moreover, the safety profile is noteworthy.
While traditional brachytherapy products emit radiation that may travel within and outside the body and have long half lives, the company's products use the Y-90 isotope, which travels only a short distance and has a half life of merely 2.7 days.
On March 15th, 2016, ADMD also announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. The IsoPet Solutions division will focus on bringing ADMD’s yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists.
ADMD expects the initial treatments to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
"I am quite excited at the opportunity to work with ADMD's team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as ADMD’s Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
Dr. Alice Villobos-
OMG you must be the biggest loser of all
Where is fakeman?
At 0,283 and 0,0298 ???
NEWS OUT
RadioGel ready to ship !!!
The Grey Muzzle Organization Welcome Alice Villalobos, DVM to the Grey Muzzle Advisory Board! Dr. Alice was elected 2016 Hermosa Beach Woman of the Year. She is President Emeritus of the Society for Veterinary Medical Ethics, Past President of the American Association of Human Animal Bond Veterinarians and Chair of the Veterinary Academy for the National Academies of Practice. She is Director of Animal Oncology Consultation Service in Woodland Hills, CA, and Pawspice at VCA Coast Animal Hospital in Hermosa Bch., CA.
http://www.greymuzzle.org/
New investor steps in before the road show starts.....
Good sign!!!
Thanks Jay
Thank god I didn't
Look like we were screwed by those people.
My profit disappeared like snow in the sun
The feeling is the same right now.
Hopefully we don't lose more money today.
Very disappointing day. Hopefully up tomorrow again
This ain't funny anymore
Must be Fakeman
I hope so !!
What the F is going on?
MELBOURNE, Australia, April 19, 2016 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the filing of two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer. The inventions summarize different combinations of the two proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance their anti-cancer effects, compared to when used in a one to one ratio, or as singular agents.
The combinations are in addition to the preferred combination for PRP, and supplements the Company's patent position across a broad range of cancers.
"When confirming PRP's effectiveness across a broad range of cancers, we also confirmed a synergistic response between the two proenzymes to the majority of cancer cell lines tested," said Dr Julian Kenyon, Propanc's Chief Scientific Officer. "We also noticed that for some cancer types, more than one combination proved to be effective, which we believe is patentable. This is extremely important, because it not only confirms the utility of our lead product, PRP, for many different cancers, but also enables us to incorporate other effective combinations as well. In total, we now have five individual patents covering PRP and also expect to file further divisional applications in various jurisdictions. We are extremely pleased with our progress as we develop a robust portfolio as leaders in the field."
"Dr Kenyon and our team of researchers have done an excellent job in continuing to grow and protect the Company's IP position," said James Nathanielsz, Propanc's Chief Executive Officer. "New, potentially patentable discoveries have also been made regarding the anti-cancer effects of proenzymes which we believe could have significant implications in the cancer treatment process. We look forward to continuing to build on this research. Furthermore, we are now preparing for what is a significant period for the Company as we turn our attention to the upcoming scientific advice meeting, preparing orphan drug designation applications and developing a strategy to engage licensing partners interested in our R&D programs, as we head towards early stage patient trials."
The Company is soon to meet with the MHRA (Medicines and Healthcare Products Regulatory Agency) to discuss formal preclinical and clinical development activities for PRP. Management also intends to apply for orphan drug designation for pancreatic and ovarian cancers in the US and EU in the near future as well, should they satisfy the necessary criteria.
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
About Propanc:
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
Logo - http://photos.prnewswire.com/prnh/20160112/321703LOGO
SOURCE Propanc Health Group Corporation
Related Links
http://www.propanc.com
Buy buy buy
April 18, 2016 8:38 AM EDT
Tweet Share E-mail
LOS ANGELES, CA -- (Marketwired) -- 04/18/16 -- StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with James C. Katzaroff, Chairman and CEO of Advanced Medical Isotope Corporation (OTC PINK: ADMD), a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non-resectable tumors, according to the Company's website (see here: www.IsotopeWorld.com). The video interview was recorded on Monday, February 22nd, 2016, at the SeeThruEquity & The Brewer Group's 2nd Annual Innovations Investor Conference 2016 in Miami, FL.
Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:
Advanced Medical Isotope Corp. -- Medical Device Company Engaged in the Development of Brachytherapy Devices for Therapeutic Applications
You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
About StockNewsNow.com
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.
Embedded Video Available:
Did dr. Alice and her team already treated dogs with radiogel? Or do we have to wait the results?
Jay,
When to expect the first result of Alice Villalobos you think?
Wow the best detailed post of the day !!
Hahaha
Haha w@nker
Let her go !!!
Do not touch the brake !!
L2 ??
77777777
Thanks P.
And with approval Admd is a big fish To catch ....
What if the vet market is booming and the fda again rejects radiogel ?
PositiveID Reports 2015 Revenue of $2.9 Million, Up 211% Year over Year
Total Assets Increase 360% to $4.7 Million
PositiveID Corporation
17 hours ago
GlobeNewswire
DELRAY BEACH, Fla., April 12, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced its financial results for the year ended December 31, 2015.
Revenue and total assets increased significantly in 2015, while the Company continued to invest in research and development as it works to complete the build and testing of its Firefly Dx handheld, real-time polymerase chain reaction (“PCR”) pathogen detection system.
“Following our acquisitions of E-N-G Mobile Systems (“ENG”) and Thermomedics in late 2015, our business is stronger and better positioned than ever to compete in the detection and diagnostics industry due to the addition of complementary revenue streams and synergistic distribution networks and customers,” stated William J. Caragol, Chairman and CEO of PositiveID. “With our continued growth and horizontal integration of our business, we are reaffirming our 2016 revenue guidance of $5-6 million.”
For the year ended December 31, 2015, revenues were $2.9 million, compared to $0.9 million for year ended December 31, 2014, an increase of 211%. Total assets for the year ended December 31, 2015 were $4.7 million, compared to $1.0 million for the year ended December 31, 2014, an increase of 360%. Revenues for 2015 included $2.5 million from a license fee paid by a large commercial partner, which had been previously deferred, and the revenue from a partial month of operations of ENG and Thermomedics. Revenue for 2014 included the proceeds from two U.S. government contracts.
The Company recorded an operating loss of $4.4 million for the year ended December 31, 2015, compared to an operating loss of $4.3 million for the year ended December 31, 2014, primarily as a result of Firefly Dx research and development expenditures, and increased selling, general and administrative expenses. The Company’s Form 10-K can be found in the Investor Relations section of its website at www.psidcorp.com.
.
.
Related Quotes
.
PSID
0.0116
-3.33%
PositiveID Corporation? Watchlist
0.0116-0.0004(3.33%)
OTC MarketsTue, Apr 12, 2016 3:59 PM EDT
POSITIVEID CORP Files SEC form 10-K, Annual Report
EDGAR Online 20 hrs ago
POSITIVEID CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
EDGAR Online 25 days ago
More
.
In 2015, the Company completed the Firefly Dx breadboard prototype and proved the Firefly Dx prototype design functions as intended through the complete sample purification and PCR detection process. The Firefly Dx prototype system successfully detected multiple pathogens, including influenza, MRSA, MSSA, E.coli, C. diff and others, in less than 30 minutes on the Firefly Dx prototype system, which is targeting the real-time PCR industry, estimated to be a $5.6 billion market by 2020. The Company is currently seeking a government or commercial partner to help fund the remaining development and build of the smaller, field-able prototype for testing by third parties in preparation for commercialization.
On December 24, 2015, PositiveID acquired ENG, a leader in mobile labs, homeland security and communications vehicles with a 25-year operating history. The acquisition of ENG will bring additional revenue and cash flow to PositiveID as well as a highly synergistic technology platform and customer base. The largest and fastest growing aspect of ENG’s business over the last decade has been its mobile labs segment, which includes chemical, biological, nuclear, radiological and explosives testing in the field. In addition to the other lines of ENG’s business, PositiveID believes it will be able to continue to grow the mobile labs segment with the addition of its leading molecular diagnostics capabilities for testing samples in the field.
In early December, PositiveID assumed control of Thermomedics, Inc., which markets the Caregiver® non-contact thermometer, a clinical grade, FDA-cleared, infrared thermometer. Infrared thermometry is experiencing the fastest growth in the global market for temperature monitoring devices, which is forecast to reach $1 billion by 2020, driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc. Caregiver’s established distribution and customer channels, including the federal government, combined with the additional qualitative synergies of an experienced management team with proven regulatory, sales, distribution and manufacturing expertise, is expected to be of great value when PositiveID reaches commercialization of Firefly Dx.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn
Fakeman want To buy your shares.
Be aware !!
Someone already listen to it?
Also on their web site as an official Announcement
sorry, wrong board.
A New Audio Interview with Advanced Medical Isotope is now at SmallCapVoice.com
04/12/2016 | 01:23pm CEST
AUSTIN, Texas, April 12, 2016 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Advanced Medical Isotope Corporation (or "AMI") (OTC:ADMD), (www.IsotopeWorld.com) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/4-11-16-smallcapvoice-interview-with-advanced-medical-isotope-corporation-admd.
AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Alice Villalobos, DVM, FNAP, Company chairperson of AMI’s new Veterinary Medicine Advisory Board called in to SmallCapVoice.com, Inc. to go over the exciting new markets and news for the Company. Recently ADMD announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market.
"The companion animal market is an area that we believe AMI will excel in. I believe that our products have great potential to enhance the quality of life for pets, an outcome that should be quite gratifying as well as a significant revenue source for the Company," stated Katzaroff.
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About Advanced Medical Isotope Corporation:
Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
Safe Harbor Statement:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACTS:
Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
509-736-4000
Investor Relations
Tyler M. Troup, B.Comm
Circadian Group IR, Managing Director
info@Circadian-Group.com
866-950-8300
For SmallCapVoice.com
Stuart T. Smith
512-267-2430
info@smallcapvoice.com